EpiCheck and Short-term Intensive Chemoresection in NMIBC
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maria S Lindgren, MD
- Phone Number: 0045 30915431
- Email: maalin@rm.dk
Study Locations
-
-
-
Aarhus, Denmark, 8200
- Recruiting
- Aarhus University Hospital
-
Contact:
- Maria S Lindgren, MD
- Phone Number: 0045 30915431
- Email: maalin@rm.dk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a known history of Ta HG with recurrent disease
- Patients referred to short-term, intensive chemoresection
- Patients older than 18 years
Exclusion Criteria:
- Known allergy or intolerance to Mitomycin
- Incontinence or small bladder capacity (< 100 mL)
- Previous pelvic radiation therapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EpiCheck result
Time Frame: One to two months after short-term, intensive chemoresection
|
Number of patients with accordance between EpiCheck score and clinical findings at the time of evaluation cystoscopy
|
One to two months after short-term, intensive chemoresection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EpiCheck result 2
Time Frame: One to two months after short-term, intensive chemoresection
|
Number of patients with discrepancy between EpiCheck score and clinical findings at the time of cystoscopy
|
One to two months after short-term, intensive chemoresection
|
|
EpiCheck result 3
Time Frame: One to two months after short-term, intensive chemoresection
|
Trend of the EpiCheck test over time (increase/decrease/stable score) and its correlation to complete/incomplete tumour response
|
One to two months after short-term, intensive chemoresection
|
|
Urine cytology
Time Frame: One to two months after short-term, intensive chemoresection
|
Sensitivity, specificity, negative and positive predictive value for urine cytology
|
One to two months after short-term, intensive chemoresection
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1-10-72-207-19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.